摘要
目的系统评价二陈汤合三子养亲汤治疗慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)的临床疗效及安全性。方法计算机检索维普全文数据库(VIP)、中国知网(CNKI)、中国生物医学文献数据库(CBM)、万方数据知识服务平台(WanFang Data)和Embase、PubMed、Web of science、Cochrane Library,收集建库至2020年5月15日国内外公开发表的关于二陈汤合三子养亲汤治疗AECOPD的随机对照试验(randomized controlled trials,RCTs)。2名研究人员根据制定的纳入、排除标准,独立进行文献筛选和相关资料的提取,描述纳入文献基本特征,并独立进行质量评价。Meta分析工具采用RevMan 5.3软件。结果12项RCTs纳入研究,共1174例患者,其中试验组590例,对照组584例。Meta分析结果显示:二陈汤合三子养亲汤能显著提高AECOPD临床有效率:RR=1.20,95%CI[1.14,1.26];显著提高FEV1(1秒用力呼气量)占预计值百分比:MD=5.80,95%CI[1.35,10.26];明显提高每分钟最大通气量(MVV)值:MD=14.86,95%CI[13.07,16.65];显著提高血氧分压(PaO2):MD=2.86,95%CI[1.27,4.44];显著降低白细胞计数(WBC):MD=-2.24,95%CI[-2.72,-1.76];显著降低中性粒细胞百分比(N%):MD=-6.93,95%CI[-7.92,-5.94];显著降低C反应蛋白(CRP):MD=-3.72,95%CI[-5.04,-2.402],且差异均具有统计学意义(P<0.05)。二陈汤合三子养亲汤治疗能降低二氧化碳分压(PaCO2):MD=-2.63,95%CI[-6.49,1.22],但结果不具有统计学意义(P>0.05)。结论二陈汤合三子养亲汤治疗AECOPD在提高临床有效率、改善肺功能、提高血氧含量、降低炎症因子方面明显优于常规治疗。
Objective To systematically review the clinical efficacy and safety of Erchen Decoction combined with Sanzi Yangqin Decoction in the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods We searched the VIP full-text database(VIP),China Knowledge Network(CNKI),China Biomedical Literature Database(CBM),WanFang Data Knowledge Service Platform(WanFang Data)and Embase,PubMed,Web of science,Cochrane Library,and collected the database built up to May 15,2020 The randomized controlled trials(RCTs)of Er Chen Tang combined with San Zi Yang Yin Decoction for the treatment of AECOPD were published at home and abroad.2 researchers independently performed literature screening and extraction of relevant information according to the established inclusion and exclusion criteria,described the basic characteristics of the included literature,and independently performed quality evaluation.the Meta-analysis tool was RevMan 5.3 software.Results Twelve RCTs were included in the study,with a total of 1174 patients,including 590 in the trial group and 584 in the control group.Meta-analysis showed that Erchen Decoction combined with Sanzi Yangqin Decoction significantly improved the clinical efficiency of AECOPD:RR=1.20,95%CI[1.14,1.26];significantly improved FEV1(exertional expiratory volume in 1 second)as a percentage of the expected value:MD=5.80,95%CI[1.35,10.26];significantly increased maximum ventilation per minute(MVV)value MD=14.86,95%CI[13.07,16.65];significantly increased partial pressure of oxygen(PaO2):MD=2.86,95%CI[1.27,4.44];significantly lowered white blood cell count(WBC):MD=-2.24,95%CI[-2.72,-1.76];significantly lowered neutrophil percentage(N%):MD=-6.93,95%CI[-7.92,-5.94];significantly lowered C-reactive protein(CRP):MD=-3.72,95%CI[-5.04,-2.402],and all differences were statistically significant(P<0.05).Treatment with E Erchen Decoction combined with Sanzi Yangqin Decoction reduced partial pressure of carbon dioxide(PaCO2):MD=-2.63,95%CI[-6.49,1.22],but the results were not statistical
作者
甘盼盼
刘玲
丁念
黄芳
Gan Panpan;Liu Ling;Ding Nian;Huang Fang(Clinical Colleges of,Hubei University of Chinese Medicine,Wuhan 430065,China;Central Hospital of Wuhan,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430014,China;Department of Pulmonary Diseases,Wuhan Hospital of Traditional Chinese Medicine,Wuhan 430060,China)
出处
《世界科学技术-中医药现代化》
CSCD
北大核心
2021年第2期597-605,共9页
Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
基金
武汉市卫计委青年基金项目(WZ19Q05):清肺止咳方破壁饮片治疗支气管扩张合并感染的临床疗效分析,负责人:甘盼盼
武汉市卫计委一般项目(WZ18E05):基于“内外合治”的益气宣肺汤联合穴位贴敷治疗老年慢性支气管炎急性发作的临床研究,负责人:黄芳。
